SAN DIEGO, July 11, 2023 /PRNewswire/ — Arthrosi Therapeutics, a clinical-stage biotechnology company, today announced the successful securing of $75 million in Series D financing. This round is led by Guangrun Health Industry (Hong Kong) Co. Limited and backed by a consortium of…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.